person · Reporting owner

SPRINGER TIMOTHY A

Disclosed activity across 4 companies

Tapewire entity: 39790
SEC CIK: 0001055624

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cartesian Therapeutics, Inc.RNAC · Entity 6015	Director · 10% owner	January 02, 2026	January 06, 2026
Tectonic Therapeutic, Inc.TECX · Entity 5328	Director · 10% owner	June 09, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cartesian Therapeutics, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,646,285	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 8,646,285 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01	Direct	7,800	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800
Common StockSEC Table I · non-derivative	IndirectBy wife	330,695	Reported balance Holding disclosure · report date 2026-01-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 330,695
Common StockSEC Table I · non-derivative	IndirectSee Footnote	656,513	Reported balance Holding disclosure · report date 2026-01-02 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 656,513 F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.

F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

Tectonic Therapeutic, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08	Direct	10,200	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-08-16 transaction · row 1 1 source row Row 1 · 2024-08-16 · Other · Disposed 4,608,052 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Common StockSEC Table I · non-derivative	IndirectSee TAS Partners LLC	Reported balance After 2024-08-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-08-16 · Other · Disposed 2,768,893 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2024-08-16 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-08-16 · Other · Disposed 42,873 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.76 · Expires 2029-04-11	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 4,288 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26	Direct	Reported balance After 2024-08-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2029-12-05	Direct	Reported balance After 2024-08-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-08-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18	Direct	Reported balance After 2024-08-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16	Direct	Reported balance After 2024-08-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-08-16 · Disposition to issuer · Disposed 9,996 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.

F4: The Company Stock Option ("Option") is fully vested.

F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Scholar Rock Holding Corp

Report date December 10, 2019 · Filed December 12, 2019

Section 16 reporting ended · disclosed 2019-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,376,567	Reported balance After 2019-12-10 transaction · row 1 1 source row Row 1 · 2019-12-10 · Gift · Disposed 296,000 · Balance 2,376,567 F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.
Common StockSEC Table I · non-derivative	IndirectBy TAS Partners, LLC	580,855	Reported balance Holding disclosure · report date 2019-12-10 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 580,855 F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.

F2: Timothy Springer is the Managing Member of TAS Partners LLC.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 10, 2026 20:45 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantStock Option (Right to Buy) · Derivative	10,200	$0.00 Strike: $28.56	$0.00	Disclosure SEC source: 0001055624-26-000003 · form4-06102026_040607.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires 2036-06-08 F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:18 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $6.76	$0.00	Disclosure SEC source: 0001453687-26-000029 · wk-form4_1767734290.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2036-01-01 Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:18 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	2,600	$0.00	$0.00	Disclosure SEC source: 0001453687-26-000029 · wk-form4_1767734290.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,646,285 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. Read SEC document
June 09, 2025 Filed Jun 11, 2025 20:30 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantStock Option (Right to Buy) · Derivative	10,200	$0.00 Strike: $24.48	$0.00	Disclosure SEC source: 0001415889-25-016672 · form4-06112025_040604.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires 2035-06-08 F1 · derivative.exercise_date: The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document
April 11, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	36,338	$10.77	$391,454.74	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 656,513 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 11, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	6,412	$10.77	$69,073.91	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,643,685 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 11, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	53,706	$16.31	$875,944.86	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,503,358 F4 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.96 to $16.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
April 11, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	9,478	$16.31	$154,586.18	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,334,846 F4 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.96 to $16.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	3,451	$10.92	$37,695.62	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 620,175 F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	45,144	$10.43	$471,055.07	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 616,724 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	609	$10.92	$6,652.17	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,637,273 Read SEC document
April 10, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	7,966	$10.43	$83,121.23	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,636,664 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 10, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	45,858	$16.73	$767,204.34	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,449,652 F3 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.29 to $17.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
April 10, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	8,092	$16.73	$135,379.16	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,325,368 F3 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.29 to $17.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	178	$9.95	$1,771.26	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 571,580 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	41,604	$9.43	$392,175.95	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 571,402 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	31	$9.95	$308.48	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,628,698 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:29 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	7,342	$9.43	$69,208.63	Disclosure SEC source: 0001453687-25-000066 · wk-form4_1744406973.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,628,667 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 09, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	4,856	$15.23	$73,956.88	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,403,794 F2 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.1994 to $15.2452 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	16,215	$14.62	$237,063.30	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,398,938 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $13.9869 to $14.9578 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
April 09, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	857	$15.23	$13,052.11	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,317,276 F2 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.1994 to $15.2452 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 09, 2025 Filed Apr 11, 2025 22:12 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	2,861	$14.62	$41,827.82	Disclosure SEC source: 0001415889-25-010588 · form4-04112025_100403.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,316,419 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $13.9869 to $14.9578 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
April 07, 2025 Filed Apr 9, 2025 21:38 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	412,500	$17.10	$7,053,750.00	Disclosure SEC source: 0001415889-25-010499 · form4-04092025_090407.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,382,723 F1 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
April 07, 2025 Filed Apr 9, 2025 21:38 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	87,500	$17.10	$1,496,250.00	Disclosure SEC source: 0001415889-25-010499 · form4-04092025_090407.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,313,558 Read SEC document
March 20, 2025 Filed Mar 20, 2025 23:50 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	54,889	$15.59	$855,593.27	Disclosure SEC source: 0001453687-25-000062 · wk-form4_1742514619.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,621,325 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.00 to $15.9222. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 19, 2025 Filed Mar 20, 2025 23:50 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	20,234	$14.97	$302,961.66	Disclosure SEC source: 0001453687-25-000062 · wk-form4_1742514619.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,566,436 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $14.85 to $15.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 18, 2025 Filed Mar 20, 2025 23:50 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	14,740	$14.42	$212,599.44	Disclosure SEC source: 0001453687-25-000062 · wk-form4_1742514619.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,546,202 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $13.7242 to $14.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:21 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	660,000	$50.00	$33,000,000.00	Disclosure SEC source: 0001415889-25-003351 · form4-02072025_090214.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 970,223 F1 · kind: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. F1 · shares: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. F2 · ownership.nature: These shares are held by TAS Partners LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:21 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	129,294	$54.14	$6,999,977.16	Disclosure SEC source: 0001415889-25-003351 · form4-02072025_090214.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,226,058 F1 · kind: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. F1 · shares: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. Read SEC document
January 14, 2025 Filed Jan 15, 2025 21:08 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	4,022	$18.00	$72,396.00	Disclosure SEC source: 0001453687-25-000047 · wk-form4_1736975300.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,531,462 Read SEC document
January 13, 2025 Filed Jan 15, 2025 21:08 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	8,983	$17.78	$159,737.50	Disclosure SEC source: 0001453687-25-000047 · wk-form4_1736975300.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,527,440 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.40 to $18.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
January 13, 2025 Filed Jan 15, 2025 21:08 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	7,962	$16.86	$134,220.21	Disclosure SEC source: 0001453687-25-000047 · wk-form4_1736975300.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,518,457 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.40 to $17.3124. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:19 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $16.93	$0.00	Disclosure SEC source: 0001453687-25-000020 · wk-form4_1736198391.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-01-01 Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:19 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	GrantCommon Stock	2,600	$0.00	$0.00	Disclosure SEC source: 0001453687-25-000020 · wk-form4_1736198391.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,510,495 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. Read SEC document
December 23, 2024 Filed Dec 23, 2024 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	5,181	$19.00	$98,436.93	Disclosure SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,507,895 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.98 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 20, 2024 Filed Dec 23, 2024 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	21,800	$18.94	$412,968.30	Disclosure SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,502,714 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.73 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 19, 2024 Filed Dec 23, 2024 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	3,376	$18.93	$63,900.93	Disclosure SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,480,914 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.82 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 19, 2024 Filed Dec 23, 2024 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	10,529	$18.35	$193,202.94	Disclosure SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,477,538 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.82 to $18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
December 19, 2024 Filed Dec 23, 2024 22:20 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	11,303	$17.39	$196,511.70	Disclosure SEC source: 0001453687-24-000147 · wk-form4_1734992437.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,467,009 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.81 to $17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
November 18, 2024 Filed Nov 19, 2024 00:35 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	20,181	$18.42	$371,736.04	Disclosure SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,455,706 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
November 18, 2024 Filed Nov 19, 2024 00:35 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	38,114	$17.96	$684,447.40	Disclosure SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,435,525 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
November 15, 2024 Filed Nov 19, 2024 00:35 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	277,246	$17.09	$4,739,187.67	Disclosure SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,397,411 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
November 14, 2024 Filed Nov 19, 2024 00:35 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	22,242	$16.97	$377,435.62	Disclosure SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,120,165 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
November 14, 2024 Filed Nov 19, 2024 00:35 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	74,157	$16.19	$1,200,720.48	Disclosure SEC source: 0001453687-24-000134 · wk-form4_1731976543.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,097,923 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
October 22, 2024 Filed Oct 24, 2024 21:04 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	300,000	$33.59	$10,077,000.00	Disclosure SEC source: 0001415889-24-025603 · form4-10242024_091007.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,096,764 Read SEC document
October 04, 2024 Filed Oct 4, 2024 21:58 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	4,879	$23.93	$116,769.11	Disclosure SEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 13 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,023,766 F12 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $23.87 to $24.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
October 04, 2024 Filed Oct 4, 2024 21:58 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	16,650	$23.57	$392,372.24	Disclosure SEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 12 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,018,887 F11 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $22.87 to $23.8699. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
October 04, 2024 Filed Oct 4, 2024 21:58 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	48,880	$22.35	$1,092,673.30	Disclosure SEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 11 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,002,237 F10 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $21.87 to $22.8626. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
October 04, 2024 Filed Oct 4, 2024 21:58 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	9,892	$21.35	$211,195.19	Disclosure SEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,953,357 F9 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $20.87 to $21.86. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
October 03, 2024 Filed Oct 4, 2024 21:58 UTC	Cartesian Therapeutics, Inc. RNAC · Entity 6015	PurchaseCommon Stock	8,043	$21.86	$175,840.09	Disclosure SEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,943,465 F8 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $21.80 to $22.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.